TuesdayOct 13, 2026 9:50 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Florida Healthcare Network With New PharmcoRx Pharmacy in Jacksonville

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions, announced the opening of a new PharmcoRx community pharmacy in Jacksonville, Florida, expanding its healthcare operations in the state. Located across from HCA Florida Memorial Hospital, the new facility offers prescription fulfillment, medication management, same-day delivery, specialty pharmacy services and patient support. The location also provides higher-margin contracted services for healthcare providers and institutions, including participants in the federal 340B drug pricing program, long-term care facilities and government agencies. PharmcoRx currently operates a network of six retail pharmacies across Florida. The expansion supports NextPlat's…

Continue Reading

TuesdayOct 13, 2026 9:10 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response. Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active…

Continue Reading

MondayOct 12, 2026 1:55 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced strong interest and engagement from orthopedic surgeons, physicians and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society ("ICRS") Summit, held Oct. 8-10 in Porto, Portugal. Discussions focused on GelrinC(R), the company's CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score ("KOOS") scores compared with historical microfracture controls at two years,…

Continue Reading

MondayOct 12, 2026 9:20 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) to Present at 2026 ThinkEquity Conference on Oct. 15

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration ("FDA") pivotal Phase III trial and preparations for commercialization in Europe, where GelrinC has received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings…

Continue Reading

WednesdayOct 07, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) , a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration “FDA”-aligned New Approach Methodologies “NAMs” across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and significantly reduce animal testing. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived…

Continue Reading

TuesdayOct 06, 2026 11:40 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD(TM) Clinical Research Business. Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an…

Continue Reading

TuesdayOct 06, 2026 9:00 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV-105 in Prostate Cancer

Kairos Pharma (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis showed a statistically significant difference in progression-free survival, with median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared with two months for those receiving apalutamide alone (P=0.0008). Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression, with patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor to be randomized to enzalutamide alone or enzalutamide in…

Continue Reading

MondayOct 05, 2026 12:03 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development. Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will…

Continue Reading

MondayOct 05, 2026 9:50 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus "BDBV" outbreak and other Ebola viruses in the Democratic Republic of Congo. The company said the trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026. Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. Pasted markdown NanoViricides said NV-387 is designed to…

Continue Reading

ThursdayOct 01, 2026 11:56 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Selects DRCARE247 as Telemedicine Partner

HealthLynked (OTCQB: HLYK) , a healthcare technology company focused on AI-powered patient engagement, care coordination and provider connectivity, selected DRCARE247 as its telemedicine partner. The partnership will integrate virtual care into the HealthLynked mobile application and website, allowing users to move from AI-powered health guidance to provider discovery, appointment scheduling, virtual consultations and medical record management within a single platform. HealthLynked expects to begin launching the integrated telemedicine platform in selected geographic regions over the next three months, followed by expansion into additional U.S. markets, subject to provider availability and applicable state requirements. The integration is expected to work alongside…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000